Website
News25/Ratings12
News · 26 weeks72-47%
2025-10-262026-04-19
Mix4690d
- Insider32(70%)
- Other9(20%)
- SEC Filings3(7%)
- Earnings2(4%)
Latest news
25 items- PRBausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular DegenerationDrawing on more than two decades of scientific evidence, a comprehensive review synthesizes more than 20 human studies highlighting the potential role of certain B vitamins in supporting eye health to help protect against age-related macular degeneration (AMD) PreserVision AREDS3™ eye vitamins combine a unique B-vitamin complex with clinically proven AREDS2 nutrients, intended to expand eye-health support to a broad range of people* PreserVision AREDS3 eye vitamins enhanced with B vitamins are now available in the U.S. and are expected to be at most major retailers by June 2026 The strength of this body of evidence has initiated planning for a long-term clinical trial to evaluate
- PRBausch + Lomb Releases 2025 Sustainability Impact ReportThe Broader Perspective framework sets direction for long-term environmental and social impact Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the release of its 2025 Sustainability Impact Report, outlining progress against its environmental, social and governance priorities and introducing The Broader Perspective, the company's sustainability framework designed to guide future action and accountability. Anchored in the belief that seeing the full picture leads to smarter decisions and greater impact, the new framework highlights how Bausch + Lomb is working across its global operations
- PRBausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling ProgramBausch + Lomb's ONE by ONE Recycling program helps prevent small, often overlooked eye health materials from entering landfills and waterways Program highlights the ongoing efforts of eye care practices, patients and consumers in collecting and recycling these used materials The initiative supports the company's long-standing environmental commitments and contributes to its FEWW sustainability metrics – fuel, energy, water and waste Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its one-of-a-kind ONE by ONE Recycling program, created in collaboration with international recycling
- SECSEC Form DEF 14A filed by Bausch + Lomb CorporationDEF 14A - Bausch & Lomb Corp (0001860742) (Filer)
- PRBausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced UpdateIncreased cutting speed of 25,000 cuts per minute1 is designed to minimize retinal traction,2 increase vitreous flow,1 and reduce infusion pressure fluctuations when used with Adaptive Fluidics.3* Bi-Blade+ provides an average flow rate increase of 25%, enabling more efficient vitreous removal compared to Bi-Blade®.1*† The resulting stability, efficiency and control help boost confidence for retina surgeons to deliver exceptional patient outcomes. Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Bi-Blad
- PRBausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in EuropeenVista Envy is the first diffractive premium IOL from Bausch + Lomb available in Europe Offers a continuous range of vision with excellent dysphotopsia tolerance EyeGility™ delivery system contributes to smooth, efficient lens delivery Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European commercial availability of the preloaded enVista Envy full range of vision intraocular lens (IOL), which offers excellent dysphotopsia tolerance on the widely used enVista IOL platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home
- PRBausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual MeetingBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of new scientific data and events taking place during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., April 10-13, 2026. Forty-five presentations and posters will highlight the results of studies evaluating the company's broad portfolio of products, including the ELIOS™ minimally-invasive glaucoma surgery (MIGS) system*, enVista Envy™ Full Visual Range and enVista Aspire™ intraocular lenses (IOLs), MIEBO® (perfluorohexyloctane ophthalmic solution), ScoutPro® point-of-care o
- PRBausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, April 29, 2025 Time: 8 a.m. ET Webcast: https://www.webcaster5.com/Webcast/Page/2883/53393 Participant Event Dial-in: +1 (888) 506-
- PRBausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of GlaucomaBoth primary effectiveness endpoints were met, demonstrating statistically significant and clinically meaningful intraocular pressure reduction. ELIOS is an implant-free procedure that uses excimer laser technology for the treatment of glaucoma. Topline results will be discussed at 1:30 p.m. ET today on the inaugural Bausch + Lomb R&D Teach-in Webinar (register here). Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced positive 24-month results from the pivotal U.S. clinical trial of the ELIOS System. Developed for the treatment of elevated intraocular pressure (IOP) in patients with
- INSIDERSEC Form 4 filed by Bausch + Lomb Corporation4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDEREVP and CFO Eldessouky Sam bought $68,520 worth of shares (4,000 units at $17.13) and was granted 4,000 shares, increasing direct ownership by 2% to 407,130 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERCEO and Chairman of the Board Saunders Brent L bought $251,958 worth of shares (14,700 units at $17.14) and was granted 14,700 shares, increasing direct ownership by 3% to 981,275 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- PRBausch + Lomb Launches R&D "Teach-in" Webinar SeriesBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D "Teach-in" webinar series that will provide deeper insights on the company's differentiated product pipeline, which was unveiled in November 2025. On Monday, March 23, 2026, at 1:30 p.m. ET, Executive Vice President of Research & Development and Chief Medical Officer Yehia Hashad, MD, will be joined by members of his leadership team to discuss two glaucoma assets: BL1107, a glaucoma medication under development that would be the first to treat vision loss in addition to lowering intraocular pressure ELIOS™, an
- INSIDERDirector Ross Thomas W. Sr. bought $79,556 worth of shares (4,500 units at $17.68) and was granted 4,500 shares, increasing direct ownership by 15% to 69,391 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERDirector Von Eschenbach Andrew C. bought $79,883 worth of shares (4,364 units at $18.30) and was granted 4,364 shares, increasing direct ownership by 14% to 70,814 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERDirector Alfonso Eduardo bought $76,970 worth of shares (4,300 units at $17.90) and was granted 4,300 shares, increasing direct ownership by 164% to 13,855 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERSVP, Controller and CAO Munsch Frederick covered exercise/tax liability with 10,171 shares, decreasing direct ownership by 9% to 98,313 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERPresident, GPIC Stewart Andrew J. covered exercise/tax liability with 4,991 shares, decreasing direct ownership by 5% to 90,649 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERPresident, Surgical Bonnefoy Luc covered exercise/tax liability with 17,936 shares, decreasing direct ownership by 15% to 100,001 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDEREVP of R&D and CMO Hashad Yehia covered exercise/tax liability with 18,865 shares, decreasing direct ownership by 9% to 180,041 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDEREVP & Chief Legal Officer Bailey A Robert D covered exercise/tax liability with 5,856 shares, decreasing direct ownership by 3% to 217,290 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDEREVP and CFO Eldessouky Sam covered exercise/tax liability with 74,039 shares, decreasing direct ownership by 16% to 399,130 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERCEO and Chairman of the Board Saunders Brent L covered exercise/tax liability with 46,708 shares, decreasing direct ownership by 5% to 951,875 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERSVP, Controller and CAO Munsch Frederick was granted 18,253 shares, increasing direct ownership by 20% to 108,484 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERPresident, Surgical Bonnefoy Luc was granted 30,373 shares, increasing direct ownership by 35% to 117,937 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)